磁共振肝细胞特异性对比剂Gd-EOB-DTPA在原发性肝癌的诊断进展
|
摘要
发性肝细胞肝癌(hepatocellular carcinoma,HCC)发病率逐年增加,早期诊断及治疗对患者预后至关重要,目前临床上已有多种影像学技术用于肝癌的诊断,但早期HCC在常规检查方法中的诊断敏感性及特异性较低。钆塞酸二钠(Gd-EOB-DTPA)作为目前应用较广泛、且具有独特成像特点的新型MRI肝细胞特异性对比剂,已越来越多应用于临床研究,尤其是肝癌的早期检出及不同进展程度肝硬化结节的鉴别诊断具有突出优势。本文就Gd-EOB-DTPA在原发性肝癌的诊断进展进行综述。
引文
[1]Willatt JM,Hussain HK,Adusumilli S,et al.MR Imaging of hepatocellular carcinoma in the cirrhotic liver:Challenges and controversies[J].Radiology,2008,247(2):311-330.
[2]Venook AP,Papandreou C,Furuse J,et al.The incidence and epidemi-ology of hepatocellular carcinoma:a global and regional perspective[J].Oncologist,2010,15suppl4:5-13.
[3]Bolog N,Andreisek G,Oancea I,et al.CT and MR imaging of hepatocellular carcinoma[J].J Gastrointestin Liver Dis,2011,20(2):181-189.
[4]Kudo M.Surveillance,diagnosis,treatment,and outcome of liver cancer in Japan[J].Liver Cancer,2015,4(1):39-50.
[5]Van Beers BE,Pastor CM,Hussain HK.Primovist,Eovist:what to expect[J].J Hepatol,2012,57(2):421-429.
[6]Ringe KI,Husarik DB,Sirlin CB,et al.Gadoxetate disodium-enhanced MRI of the liver:part 1,protocol optimization and lesion appearance in the noncirrhotic liver[J].AJR,2010,195(1):13-28.
[7]International Working Party.Terminology of nodular hepatocellular lesions[J].Hepatology,1995,22(3):983-993.
[8]Golfieri R,Renzulli M,Lucidi V,et al.Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to dynamic MRI in the detection of hypovascular small(≤2 cm)HCC in cirrhosis[J].Eur Radiol,2011,21(6):1233-1242.
[9]Willatt JM,Hussain HK,Adusumilli S,et al.MRImaging of hepatocellular carcinoma in the cirrhotic liver:challenges and controversies[J].Radiology,2008,24(2):311-330.
[10]Golfieri R,Grazioli L,Orlando E,et al.Which is the best MRI marker of malignancy for atypical cirrhotic nodules:hypointensity in hepatobiliary phase alone or combined with other features?Classification after Gd-EOB-DTPA administration[J].JMagn Reson Imaging,2012,36(3):648-657.
[11]Motosugi U,Ichikawa T,Sano K,et al.Outcome of hypovascular hepatic nodules revealing no gadoxetic acid uptake in patients with chronic liver disease[J].J Magn Reson Imaging,2011,34(1):88-94.
[12]Saitoh T,Soto S,Yazaki T,Tobita H,el a1.Progression of Hepatic Hypovascular Nodules with Hypointensity in the Hepatobiliary Phase of Gd-EOB-DT-PA-enhanced MRI in Hepatocellular Carcinoma Cases[J].Inter Med,2018,57(2):165-171
[13]Imbriaco M,De Luca S,Coppola M,Fusari M,Klain M,et al.Diagnostic Accuracy of Gd-EOB-DTPA for Detection Hepatocellular Carcinoma(HCC):A Comparative Study with Dynamic Contrast Enhanced Magn-etic Resonance Imaging(MRI)and Dynamic Contrast Enhanced Compu-ted Tomography(CT)[J].Pol J Radiol,2017,82:50-57.
[14]DING Y,CHEN CZ,RAO SX,et al.A compared study on Gd-EOB-DTPA and Gd-DTPA-enhanced MRI in detection of hepato-cellular carcinoma[J].Chin J Gen Surg,2013,28(9):682-685.
[15]KIERANS AS,KANG SK,ROSENK RANTZ AB.The diagnostic performance of dynamic contrast-enhanced MR imaging for detection of small hepatocellular carcinoma measuring up to 2 cm:a meta analysis[J].Radiology,2016,278(1):82-94.
[16]Murakami T,Okada M,Hyodo T,et al.CT versus MRimaging of hepatocellular carcinoma:toward improved treatment decisions[J].Magn Reson Med Sci,2012,11(2):75-81.
[17]Di Martino M,Marin D,Guerrisi A,et al.Intra-individual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the Detection of hepatocellular carcinoma in patients with cirrhosis[J].Radiology,2010,256(2):806-816
[18]Sano K,Ichikawa T,Motosugi U,et al.Imaging study of early hepatocellular carcinoma:usefulness of gadoxetic acid-enhanced MR imaging[J].Radiology,2011,261(3):834-844.
[19]Frericks BB,Loddenkemper C,Huppertz A,et al.Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA[J].AJR Am J Roentgenol,2009,193(4):1053-1060
[20]Lee SA,Lee CH,Jung WY,et al.Paradoxical high signal intensity of hepatocellular carcinoma in the hepatobiliary phase of Gd-EOB-DTPA enhanced MRI:initial experience[J].Magn Reson Imaging,2011,29(1):83-90.
[21]Narita M,Hatano E,Arizono S,et al.Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma[J].J Gastroenterol,2009,44(7):793-798.
[22]Asayama Y,Tajima T,Nishie A,et al.Uptake of GdEOB-DTPA by hepatocellular carcinoma:radiologicpathologic correlation with special reference to bile production[J].Eur J Radiol,2011,80(3):243-248.
[23]Yi-chun Wang,Chen-te Chou,Ching-po Lin,et al.The value of Gd-EOB-DTPA-enhanced MR imaging in characterizing cirrhotic nodules with atypical enhancement on Gd-DTPA-enhanced MR images[J].PLOSONE,2017,12(3):e0174594.
[24]Doo KW,Lee CH,Choi JW,et al."Pseudo washout"sign in highflow hepatic hemangioma on gadoxetic acid contrast-enhanced MRI mimicking hypervascular tumor[J].AJR,2009,193(6):490-496.
[25]MOTOSUGI U,ICHIKAWA T,SOU H,et al.Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging[J].Radiology,2010,256(1):151-158
[26]Suh YJ,Kim MJ,Choi JY,et al.Differentiation of hepatic hyperintense lesions seen on gadoxetic acidenhanced hepatobiliary phase MRI[J].AJR,2011,197(1):44-52.
[2]Venook AP,Papandreou C,Furuse J,et al.The incidence and epidemi-ology of hepatocellular carcinoma:a global and regional perspective[J].Oncologist,2010,15suppl4:5-13.
[3]Bolog N,Andreisek G,Oancea I,et al.CT and MR imaging of hepatocellular carcinoma[J].J Gastrointestin Liver Dis,2011,20(2):181-189.
[4]Kudo M.Surveillance,diagnosis,treatment,and outcome of liver cancer in Japan[J].Liver Cancer,2015,4(1):39-50.
[5]Van Beers BE,Pastor CM,Hussain HK.Primovist,Eovist:what to expect[J].J Hepatol,2012,57(2):421-429.
[6]Ringe KI,Husarik DB,Sirlin CB,et al.Gadoxetate disodium-enhanced MRI of the liver:part 1,protocol optimization and lesion appearance in the noncirrhotic liver[J].AJR,2010,195(1):13-28.
[7]International Working Party.Terminology of nodular hepatocellular lesions[J].Hepatology,1995,22(3):983-993.
[8]Golfieri R,Renzulli M,Lucidi V,et al.Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to dynamic MRI in the detection of hypovascular small(≤2 cm)HCC in cirrhosis[J].Eur Radiol,2011,21(6):1233-1242.
[9]Willatt JM,Hussain HK,Adusumilli S,et al.MRImaging of hepatocellular carcinoma in the cirrhotic liver:challenges and controversies[J].Radiology,2008,24(2):311-330.
[10]Golfieri R,Grazioli L,Orlando E,et al.Which is the best MRI marker of malignancy for atypical cirrhotic nodules:hypointensity in hepatobiliary phase alone or combined with other features?Classification after Gd-EOB-DTPA administration[J].JMagn Reson Imaging,2012,36(3):648-657.
[11]Motosugi U,Ichikawa T,Sano K,et al.Outcome of hypovascular hepatic nodules revealing no gadoxetic acid uptake in patients with chronic liver disease[J].J Magn Reson Imaging,2011,34(1):88-94.
[12]Saitoh T,Soto S,Yazaki T,Tobita H,el a1.Progression of Hepatic Hypovascular Nodules with Hypointensity in the Hepatobiliary Phase of Gd-EOB-DT-PA-enhanced MRI in Hepatocellular Carcinoma Cases[J].Inter Med,2018,57(2):165-171
[13]Imbriaco M,De Luca S,Coppola M,Fusari M,Klain M,et al.Diagnostic Accuracy of Gd-EOB-DTPA for Detection Hepatocellular Carcinoma(HCC):A Comparative Study with Dynamic Contrast Enhanced Magn-etic Resonance Imaging(MRI)and Dynamic Contrast Enhanced Compu-ted Tomography(CT)[J].Pol J Radiol,2017,82:50-57.
[14]DING Y,CHEN CZ,RAO SX,et al.A compared study on Gd-EOB-DTPA and Gd-DTPA-enhanced MRI in detection of hepato-cellular carcinoma[J].Chin J Gen Surg,2013,28(9):682-685.
[15]KIERANS AS,KANG SK,ROSENK RANTZ AB.The diagnostic performance of dynamic contrast-enhanced MR imaging for detection of small hepatocellular carcinoma measuring up to 2 cm:a meta analysis[J].Radiology,2016,278(1):82-94.
[16]Murakami T,Okada M,Hyodo T,et al.CT versus MRimaging of hepatocellular carcinoma:toward improved treatment decisions[J].Magn Reson Med Sci,2012,11(2):75-81.
[17]Di Martino M,Marin D,Guerrisi A,et al.Intra-individual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the Detection of hepatocellular carcinoma in patients with cirrhosis[J].Radiology,2010,256(2):806-816
[18]Sano K,Ichikawa T,Motosugi U,et al.Imaging study of early hepatocellular carcinoma:usefulness of gadoxetic acid-enhanced MR imaging[J].Radiology,2011,261(3):834-844.
[19]Frericks BB,Loddenkemper C,Huppertz A,et al.Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA[J].AJR Am J Roentgenol,2009,193(4):1053-1060
[20]Lee SA,Lee CH,Jung WY,et al.Paradoxical high signal intensity of hepatocellular carcinoma in the hepatobiliary phase of Gd-EOB-DTPA enhanced MRI:initial experience[J].Magn Reson Imaging,2011,29(1):83-90.
[21]Narita M,Hatano E,Arizono S,et al.Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma[J].J Gastroenterol,2009,44(7):793-798.
[22]Asayama Y,Tajima T,Nishie A,et al.Uptake of GdEOB-DTPA by hepatocellular carcinoma:radiologicpathologic correlation with special reference to bile production[J].Eur J Radiol,2011,80(3):243-248.
[23]Yi-chun Wang,Chen-te Chou,Ching-po Lin,et al.The value of Gd-EOB-DTPA-enhanced MR imaging in characterizing cirrhotic nodules with atypical enhancement on Gd-DTPA-enhanced MR images[J].PLOSONE,2017,12(3):e0174594.
[24]Doo KW,Lee CH,Choi JW,et al."Pseudo washout"sign in highflow hepatic hemangioma on gadoxetic acid contrast-enhanced MRI mimicking hypervascular tumor[J].AJR,2009,193(6):490-496.
[25]MOTOSUGI U,ICHIKAWA T,SOU H,et al.Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging[J].Radiology,2010,256(1):151-158
[26]Suh YJ,Kim MJ,Choi JY,et al.Differentiation of hepatic hyperintense lesions seen on gadoxetic acidenhanced hepatobiliary phase MRI[J].AJR,2011,197(1):44-52.